Monoclonal antibodies for migraine prevention: hope hype and health economy challenge

摘要

The annual prevalence of migraine in the UK is 7.6% in males and 18.3% in females.1 Migraine is ranked globally as the second most disabling disease,2 and is the second most frequent cause of short-term absence for non-manual employees with a cost of 2.25 billion GBP per year in the UK.1 Over 30% of people with migraine have ≥4 attacks a month, of whom a quarter will have chronic migraine — arbitrarily defined as headache on ≥15 days of the month, of which eight are migraine.3 Chronic migraine has a high impact and is associated with medication overuse headache and deteriorating psychosocial functioning.3